Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Cost of Revenue: 2021-2024

Historic Cost of Revenue for BridgeBio Pharma (BBIO) over the last 4 years, with Dec 2024 value amounting to $3.9 million.

  • BridgeBio Pharma's Cost of Revenue rose 997.49% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year increase of 524.54%. This contributed to the annual value of $3.9 million for FY2024, which is 58.54% up from last year.
  • As of FY2024, BridgeBio Pharma's Cost of Revenue stood at $3.9 million, which was up 58.54% from $2.4 million recorded in FY2023.
  • BridgeBio Pharma's 5-year Cost of Revenue high stood at $3.9 million for FY2024, and its period low was $2.4 million during FY2023.
  • Over the past 3 years, BridgeBio Pharma's median Cost of Revenue value was $3.4 million (recorded in 2022), while the average stood at $3.3 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first dropped by 28.77% in 2023, then spiked by 58.54% in 2024.
  • BridgeBio Pharma's Cost of Revenue (Yearly) stood at $3.1 million in 2021, then climbed by 10.28% to $3.4 million in 2022, then declined by 28.77% to $2.4 million in 2023, then spiked by 58.54% to $3.9 million in 2024.